Gregg C Fonarow1, Adrian F Hernandez2, Scott D Solomon3, Clyde W Yancy4. 1. The Ahmanson-UCLA (University of California, Los Angeles) Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles2Associate Editor for Health Care Quality and Guidelines, JAMA Cardiology. 2. Duke Clinical Research Institute, Durham, North Carolina4Associate Editor, JAMA Cardiology. 3. TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts. 4. Northwestern University, Feinberg School of Medicine, Chicago, Illinois7Deputy Editor, JAMA Cardiology.
Abstract
IMPORTANCE: Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) in clinical trials. To date, estimation of the potential benefits that could be gained from optimal implementation of ARNI therapy at the population level have not been quantified. OBJECTIVE: To quantify the projected gains for deaths prevented or postponed with comprehensive implementation of ARNI therapy for patients with HFrEF in the United States. DESIGN, SETTING, AND PARTICIPANTS: Eligibility criteria for ARNI therapy, population-based estimates of patients with HFrEF in the United States, and numbers needed to treat to overt death were obtained from published sources. The potential numbers of deaths prevented or postponed as a result of ARNI were estimated along with multiple-way sensitivity analysis. MAIN OUTCOME AND MEASURE: All-cause mortality. RESULTS: Of 2 736 000 patients with HFrEF patients in the United States, 2 287 296 (84%) were projected to be candidates for ARNI therapy. Optimal implementation of ARNI therapy was empirically estimated to prevent 28 484 deaths a year (range, 18 230-41 017 deaths per year). CONCLUSIONS AND RELEVANCE: A substantial number of deaths in the United States could potentially be prevented by optimal implementation of ARNI therapy. These data support implementation of evidence into practice in a timely manner because this may have a material impact on population health among patients with HFrEF.
IMPORTANCE: Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) in clinical trials. To date, estimation of the potential benefits that could be gained from optimal implementation of ARNI therapy at the population level have not been quantified. OBJECTIVE: To quantify the projected gains for deaths prevented or postponed with comprehensive implementation of ARNI therapy for patients with HFrEF in the United States. DESIGN, SETTING, AND PARTICIPANTS: Eligibility criteria for ARNI therapy, population-based estimates of patients with HFrEF in the United States, and numbers needed to treat to overt death were obtained from published sources. The potential numbers of deaths prevented or postponed as a result of ARNI were estimated along with multiple-way sensitivity analysis. MAIN OUTCOME AND MEASURE: All-cause mortality. RESULTS: Of 2 736 000 patients with HFrEF patients in the United States, 2 287 296 (84%) were projected to be candidates for ARNI therapy. Optimal implementation of ARNI therapy was empirically estimated to prevent 28 484 deaths a year (range, 18 230-41 017 deaths per year). CONCLUSIONS AND RELEVANCE: A substantial number of deaths in the United States could potentially be prevented by optimal implementation of ARNI therapy. These data support implementation of evidence into practice in a timely manner because this may have a material impact on population health among patients with HFrEF.
Authors: Adam P Bress; Holly Kramer; Rasha Khatib; Srinivasan Beddhu; Alfred K Cheung; Rachel Hess; Vinod K Bansal; Guichan Cao; Jerry Yee; Andrew E Moran; Ramon Durazo-Arvizu; Paul Muntner; Richard S Cooper Journal: Circulation Date: 2017-02-13 Impact factor: 29.690
Authors: Poghni A Peri-Okonny; Xiaojuan Mi; Yevgeniy Khariton; Krishna K Patel; Laine Thomas; Gregg C Fonarow; Puza P Sharma; Carol I Duffy; Nancy M Albert; Javed Butler; Adrian F Hernandez; Kevin McCague; Fredonia B Williams; Adam D DeVore; J Herbert Patterson; John A Spertus Journal: JACC Heart Fail Date: 2019-02-06 Impact factor: 12.035
Authors: Ashlay A Huitema; Alexia Daoust; Kim Anderson; Stephanie Poon; Sean Virani; Michel White; Carlos Rojas-Fernandez; Shelley Zieroth; Robert S McKelvie Journal: CJC Open Date: 2020-04-05
Authors: Pratyaksh K Srivastava; Brian L Claggett; Scott D Solomon; John J V McMurray; Milton Packer; Michael R Zile; Akshay S Desai; Jean L Rouleau; Karl Swedberg; Gregg C Fonarow Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Adam P Bress; Lisandro D Colantonio; Richard S Cooper; Holly Kramer; John N Booth; Michelle C Odden; Kirsten Bibbins-Domingo; Daichi Shimbo; Paul K Whelton; Emily B Levitan; George Howard; Brandon K Bellows; Dawn Kleindorfer; Monika M Safford; Paul Muntner; Andrew E Moran Journal: Circulation Date: 2019-01-02 Impact factor: 29.690
Authors: Arjun Sinha; Deepak K Gupta; Clyde W Yancy; Sanjiv J Shah; Laura J Rasmussen-Torvik; Elizabeth M McNally; Philip Greenland; Donald M Lloyd-Jones; Sadiya S Khan Journal: Circ Heart Fail Date: 2021-02-04 Impact factor: 8.790
Authors: Yuling Yan; Bin Liu; Jun Du; Jing Wang; Xiaodong Jing; Yajie Liu; Songbai Deng; Jianlin Du; Qiang She Journal: ESC Heart Fail Date: 2021-03-21